In short
This article discusses clinical trials involving the use of pertussis pertactin adsorbed on aluminium hydroxide, hydrated and aluminium phosphate as a component in combination vaccines. These trials aim to evaluate the safety, effectiveness, and immune response of vaccines containing this pertussis antigen along with other components like diphtheria and tetanus toxoids. The studies focus on assessing the vaccines' ability to protect against whooping cough (pertussis) as well as diphtheria and tetanus when administered to various age groups.
At a glance
- Vaccine Components
- Pertussis pertactin, diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous hemagglutinin
- Adjuvant
- Aluminium hydroxide, hydrated and aluminium phosphate
- Administration
- Intramuscular injection, typically 0.5 ml dose
- Target Population
- Adolescents and adults for booster vaccination
- Clinical Trial Objectives
- Evaluate safety, effectiveness, immunogenicity, and reactogenicity
- Primary Endpoints
- Antibody concentrations, adverse events (local and systemic)
- Secondary Endpoints
- Medically attended adverse events (MAAEs)
- Study Design
- Randomized, observer-blind trials with various administration groups
- Follow-up Period
- Typically up to 28 days after each dose, with longer monitoring for safety
What is Pertussis Pertactin?
Pertussis pertactin is a component of vaccines used to prevent whooping cough (pertussis). It is a protein found on the surface of the bacteria that causes pertussis, Bordetella pertussis. When included in vaccines, pertussis pertactin helps stimulate the immune system to produce antibodies against the bacteria, providing protection against the disease.
Vaccine Composition
The vaccine containing pertussis pertactin is typically part of a combination vaccine that protects against multiple diseases. The full composition includes:
- Diphtheria toxoid: Provides protection against diphtheria
- Tetanus toxoid: Offers immunity against tetanus
- Pertussis components:
- Pertussis toxoid
- Pertussis filamentous hemagglutinin
- Pertussis pertactin
All these components are adsorbed on aluminum hydroxide (hydrated) and aluminum phosphate, which act as adjuvants to enhance the immune response.
Medical Conditions Treated
This vaccine is primarily used for the prevention of three infectious diseases:
- Pertussis (whooping cough): A highly contagious respiratory disease characterized by severe coughing fits
- Diphtheria: A serious bacterial infection affecting the mucous membranes of the nose and throat
- Tetanus: A severe disease caused by a toxin-producing bacteria that affects the nervous system
The vaccine containing pertussis pertactin is used for both primary immunization in children and booster doses in adolescents and adults.
Administration
The vaccine is administered as an intramuscular injection, typically in the deltoid muscle (upper arm) for adolescents and adults. The standard dose is 0.5 ml. For primary immunization, multiple doses are given according to the recommended vaccination schedule. Booster doses may be recommended at specific intervals or in certain situations, such as pregnancy or potential exposure to pertussis.
Effectiveness and Safety
Clinical trials have shown that vaccines containing pertussis pertactin are effective in preventing pertussis, diphtheria, and tetanus. The immune response is measured by the concentration of antibodies produced against each component of the vaccine. For example, after vaccination, individuals typically show anti-tetanus toxoid and anti-diphtheria toxoid antibody concentrations ≥0.1 IU/mL, which is considered protective.
Potential Side Effects
Like all vaccines, those containing pertussis pertactin can cause side effects, although not everyone experiences them. Common side effects may include:
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Fever
- Nausea
These reactions are usually mild and resolve within a few days. Serious allergic reactions are rare but can occur.
Precautions and Contraindications
The vaccine should not be given to individuals with:
- A history of severe allergic reaction to any component of the vaccine
- A history of severe adverse reaction associated with a previous dose of the vaccine
- Acute febrile illness (the vaccination should be postponed)
Pregnant women should consult their healthcare provider before receiving the vaccine. While it is generally considered safe during pregnancy, the potential risks and benefits should be evaluated on an individual basis.